Spark Therapeutics, Inc. (Nasdaq: ONCE) to Ring The Nasdaq Stock Market Opening Bell
March 27 2015 - 10:00AM
What:
Spark Therapeutics, Inc. (Nasdaq:ONCE) will visit the Nasdaq
MarketSite in Times Square to celebrate its recent initial public
offering. Spark is a late clinical-stage gene therapy company
seeking to transform the lives of patients suffering from
debilitating genetic diseases by developing one-time, life-altering
treatments.
In honor of the occasion, Jeffrey D. Marrazzo,
Co-Founder and Chief Executive Officer, will ring the
Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Monday, March 30, 2015 – 9:15 a.m. to 9:30 a.m.
ET
Spark Therapeutics, Inc. Media Contact:Jessica
Rowlands(202) 729-4089Jessica. Rowlands@fkhealth.com
Nasdaq MarketSite:Christine Barna(646)
441-5310Christine.Barna@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram
Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page
at: http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr
Page: http://nasdaq.tumblr.com/
Webcast:
A webcast of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Open, please
go to http://www.nasdaq.com/reference/marketsite_events.stm and
click on the market open of your choice.
About Spark Therapeutics, Inc.
(Nasdaq:ONCE):
Spark is a gene therapy leader seeking to transform the lives of
patients suffering from debilitating genetic diseases by developing
one-time, life-altering treatments. Spark's initial focus is on
treating orphan diseases where no, or only palliative, therapies
exist. Spark's most advanced product candidate, SPK-RPE65, which
has received both breakthrough therapy and orphan product
designation, is in a fully enrolled pivotal Phase 3 clinical trial
for the treatment of rare blinding conditions. Spark is leveraging
the experience and technology utilized in the development of
SPK-RPE65 to address a broad spectrum of blinding conditions,
starting with the development of SPK-CHM for the potential
treatment of choroideremia, currently in a Phase 1/2 clinical
trial. Spark also is establishing a pipeline of gene therapy
candidates to treat hematologic disorders and neurodegenerative
diseases, including through a global collaboration with Pfizer Inc.
around the development and commercialization of its SPK-FIX program
for the treatment of hemophilia B. Spark's integrated gene therapy
platform builds on two decades of research, development and
manufacturing at The Children's Hospital of Philadelphia, including
human trials conducted across diverse therapeutic areas and routes
of administration. To learn more, please visit www.sparktx.com.
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing,
exchange technology, listing, information and public company
services across six continents. Through its diverse portfolio of
solutions, Nasdaq enables customers to plan, optimize and execute
their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 70
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to more than 3,500 listed companies
with a market value of over $9.1 trillion and more than 10,000
corporate clients. To learn more, visit www.nasdaq.com/ambition or
www.business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024